An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...
Tulisokibart is a tumor necrosis factor–like cytokine 1A (TL1A) monoclonal antibody in development for the treatment of moderately to severely active ulcerative colitis. A genetic-based diagnostic ...
According to the National Institutes of Health, between 600,000 and 900,000 Americans have ulcerative colitis, a chronic inflammatory disease of the large intestine. While treatments for the disease ...
Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...
Living with ulcerative colitis means navigating a complex and often unpredictable digestive condition that impacts daily life in profound ways. This inflammatory bowel disease affects approximately 1 ...
Credit: Getty Images. Medications for ulcerative colitis include first-line therapy 5-ASA for mild cases as well as immune system–altering biologics for more severe cases. The initial treatment with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results